**The Original Typhoid Conjugate Vaccine**

**Tybar Plus**

**MISSION 7 BILLION**

Tybar Plus is a weapon against the high but underappreciated burden of typhoid fever in children and adults.

- Dr. M. K. Venk, Former Secretary, Department of Biotechnology, Govt. of India

With this new vaccine, countries will finally be able to protect millions of children who are most vulnerable to this deadly disease.

- Dr. Anil Prabhu, Director of Vaccine Development, Serum Institute, and Ethics and Outcomes Classes, Bill & Melinda Gates Foundation

Tybar Plus can be incorporated into routine vaccination schedules, giving us the best chance to reach children at risk for this devastating disease.

- Dr. Kathy Hewitt, Director - Centers for Vaccine Development, at the University of Maryland School of Medicine

The typhoid conjugate vaccine will not only save lives, but also bolster the fight against antimicrobial drug-resistance. Expanding vaccine coverage will play an important role in reducing diseases and death from typhoid. Gavi is looking forward to working with governments to support the introduction of this safe and effective vaccine.

- Dr. Seth Berkley, CEO - Gavi, the Vaccine Alliance

---

**Typhoid Vaccination Development with a Human Challenge Model**

The new oral typhoid conjugate vaccine, Tybar Plus (YVP), eliciting robust vaccine-induced antibody responses after only 1 dose in Indian children as young as 6 months old. The vaccine was evaluated in a trial, which showed that the YVP is well tolerated, eliciting 100% seroconversion of antibody with efficacy of 87.1%.

- Prof. Andrew Pollard, Professor of Paediatric Infection and Immunology, University of Oxford

---

**Global Effectiveness Study - Vaccine Trial Kick-Off**

Clinical trials of the new Tybar Plus are being conducted to further evaluate vaccine efficacy and impact of a typhoid conjugate vaccine in reducing typhoid burden in endemic countries.

- Board of Gavi, the Vaccine Alliance approved US$ 85 million for FY19-20 to support its introduction in developing countries.

  - [India] ~ 25,000 subjects
  - [Bangladesh] ~ 50,000 subjects
  - [Pakistan] ~ 250,000 subjects
  - [Mumbai (India)] ~ 200,000 subjects

In partnership with:

- Bill & Melinda Gates Foundation
- Stanford University
- CDC
- University of Maryland
- TyVAC